08:07 AM EDT, 05/16/2024 (MT Newswires) -- (Corrects the reporting day in the first paragraph.)

Arvinas ( ARVN ) and Pfizer ( PFE ) said Thursday that updated data from a phase 1b study evaluating metastatic breast cancer drug candidate vepdegestrant in combination with palbociclib for the treatment of advanced breast cancer demonstrated encouraging clinical activity.

The study evaluated the combination of vepdegestrant and palbociclib with the involvement of heavily pre-treated patients with a median of four lines of prior therapy with locally advanced or metastatic ER-positive/human epidermal growth factor 2 negative breast cancer.

The new data presented at the 2024 European Society for Medical Oncology Breast Cancer Annual Congress aligns with previous findings shared at the San Antonio Breast Cancer Symposium in December 2023.

The combination of vepdegestrant and palbociclib showed an "encouraging clinical benefit rate, objective response rate and progression-free survival, and a consistent safety profile," Arvinas ( ARVN ) said.

Price: 35.71, Change: +3.38, Percent Change: +10.45